Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Sickle Cell Disease
Interventions: Music Therapy, Music Listening; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Transfusion, Blood, Chelation therapy; Procedure · Biological
Lead sponsor: Columbia University; Other
Eligibility: 1 Year to 65 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452; Biological · Device
Lead sponsor: Daniel Bauer; Other
Eligibility: 13 Years to 35 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, COVID-19 Vaccine, Vaccine Hesitancy
Interventions: SCD-specific COVID-19 vaccination information (SCVI) video; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anemia, Sickle Cell
Interventions: pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: Placebo, Zoledronic Acid; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Death, Sudden, Cardiac
Interventions: Implantable cardioverter-defibrillator (ICD); Device
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia, Sickle Cell Hemoglobin C
Interventions: MED-Go App; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury
Interventions: Selective Cytopheretic Device; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Birmingham, Alabama • Cincinnati, Ohio

Conditions: Sudden Cardiac Death
Interventions: Not listed
Lead sponsor: Harbinger Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Phoenix, Arizona • Wichita, Kansas • Boston, Massachusetts + 1 more

Conditions: Sickle Cell Disease, Sickle Cell Hemoglobin C, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia
Interventions: PROs assessment using sickle cell disease mobile app (SCD-app); Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions: Bone marrow transplantation, Mesenchymal Stromal Cells; Procedure · Biological
Lead sponsor: Stanford University; Other
Eligibility: 1 Year to 25 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Birmingham, Alabama • Minneapolis, Minnesota

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Sickle Cell Disease, Kidney Injury, Kidney Diseases, Kidney Disease, Chronic
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 25 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sudden Cardiac Arrest
Interventions: Machine learning-guided cardiac arrest prediction device; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Disease
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Sickle Cell Disease
Interventions: Oxypurinol, L-NMMA, Acetylcholine; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiac Arrest, Sudden Cardiac Arrest
Interventions: DFR AED Pilot Program; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Clemmons, North Carolina

Conditions: Sickle Cell Disease
Interventions: Nicotinamide; Drug
Lead sponsor: EpiDestiny, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease, Renal Disease, Glomerular Disease
Interventions: iohexol GFR; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 5 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Birmingham, Alabama • Chicago, Illinois • Memphis, Tennessee

Conditions: Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Interventions: natural product combination-1 (NPC1); Combination Product
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Acute Chest Syndrome
Interventions: Exhaled Breath Condensate (EBC), Plasma Sample; Diagnostic Test
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 7 Years to 30 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Priapism, Anemia, Sickle Cell
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 5 Years and older · Male only
Enrollment: 1,464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 27
States / cities: Mobile, Alabama • Davis, California • Oakland, California + 16 more

Search by objective public record fields.

Music Therapy in Sickle Cell Pain Mixed Methods Study

Effects of Transfusion of Older Stored Red Cells

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease

COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI

Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias

Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

Exploring Adherence Monitoring in Sickle Cell Disease

Acute Kidney Injury in Patients With Sickle Cell Disease

AI-guided Prediction and Treatment of Cardiac Arrest

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

Developing and Testing Drone-Delivered AEDs for Cardiac Arrests In Rural America

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

sPLA2 in EBC During Acute Chest Syndrome

Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence